Soligenix Inc. Watch

from S-1 9 pages ​ ​ [•], 2024 Soligenix, Inc. Attention: Christopher J. Schaber, President and Chief Executive Officer 29 Emmons Drive, Suite B-10 Princeton, Nj 08540 Re: Placement Agency Agreement Dear Dr. Schaber

from S-1/A 9 pages ​ ​ April [•], 2023 Soligenix, Inc. Attention: Christopher J. Schaber, President and Chief Executive Officer 29 Emmons Drive, Suite B-10 Princeton, Nj 08540 Re: Placement Agent Agreement Dear Dr. Schaber

from S-1/A 53 pages Underwriting Agreement Between Soligenix, Inc. and A.G.P./ALLIANCE Global Partners, as Representative of the Several Underwriters

from SC 13G/A ~5 pages Joint Filing Agreement

from SC 13G ~5 pages Joint Filing Agreement

from 10-Q 45 pages Soligenix, Inc. Common Stock (Par Value $0.001 Per Share) at Market Issuance Sales Agreement

from S-1/A 45 pages Form of Underwriting Agreement Between Soligenix, Inc. and Aegis Capital Corp., as Representative of the Several Underwriters Soligenix, Inc. Underwriting Agreement

from S-1/A 34 pages Soligenix, Inc. ● Units Each Unit Consisting of One Share of Common Stock and ● of a Warrant, Each to Purchase One Share of Common Stock Form of Underwriting Agreement

from S-1/A 29 pages Form of Placement Agency Agreement

from S-1/A 29 pages Form of Placement Agency Agreement

from SC 13G/A ~5 pages Joint Filing Agreement

from SC 13G/A ~1 page Joint Filing Agreement

from SC 13G 1 page Exhibit 1.1 Joint Filing Agreement the Undersigned Hereby Agree That the Statement on This Schedule 13g, Dated November 14, 2003, (The "Schedule 13g"), With Respect to the Common Stock, Par Value $.001 Per Share, of Dor Biopharma,inc. Is Filed on Behalf of Each of US Pursuant to and in Accordance With the Provisions of Rule 13d-1(k) Under the Securities and Exchange Act of 1934, as Amended, and That This Agreement Shall Be Included as an Exhibit to This Schedule 13g. Each of the Undersigned Agrees to Be Responsible for the Timely Filing of the Schedule 13g, and for the Completeness and Accuracy of the Information Concerning Itself Contained Therein. This Agreement May Be Executed in Any Number of Counterparts, All of Which Taken Together Shall Constitute One and the Same Instrument. in Witness Whereof, the Undersigned Have Executed This Agreement as of the 14th Day of November, 2003. Orbimed Advisors LLC By: /S/ Samuel D. Isaly Name: Samuel D. Isaly Title: Managing Member Orbimed Capital LLC By: /S/ Samuel D. Isaly Name: Samuel D. Isaly Title: Managing Member By: /S/ Samuel D. Isaly Name: Samuel D. Isaly <page>

from SC 13G 1 page Exhibit 1.1 Joint Filing Agreement the Undersigned Hereby Agree That the Statement on This Schedule 13g, Dated November 14, 2003, (The "Schedule 13g"), With Respect to the Common Stock, Par Value $.001 Per Share, of Dor Biopharma,inc. Is Filed on Behalf of Each of US Pursuant to and in Accordance With the Provisions of Rule 13d-1(k) Under the Securities and Exchange Act of 1934, as Amended, and That This Agreement Shall Be Included as an Exhibit to This Schedule 13g. Each of the Undersigned Agrees to Be Responsible for the Timely Filing of the Schedule 13g, and for the Completeness and Accuracy of the Information Concerning Itself Contained Therein. This Agreement May Be Executed in Any Number of Counterparts, All of Which Taken Together Shall Constitute One and the Same Instrument. in Witness Whereof, the Undersigned Have Executed This Agreement as of the 14th Day of November, 2003. Orbimed Advisors LLC By: /S/ Samuel D. Isaly Name: Samuel D. Isaly Title: Managing Member Orbimed Capital LLC By: /S/ Samuel D. Isaly Name: Samuel D. Isaly Title: Managing Member By: /S/ Samuel D. Isaly Name: Samuel D. Isaly <page>